These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 24697296)
41. Firibastat, the first-in-class brain aminopeptidase a inhibitor, in the management of hypertension: A review of clinical trials. Alomar SA; Alghabban SA; Alharbi HA; Almoqati MF; Alduraibi Y; Abu-Zaid A Avicenna J Med; 2021; 11(1):1-7. PubMed ID: 33520782 [TBL] [Abstract][Full Text] [Related]
42. Involvement of arginine 878 together with Ca2+ in mouse aminopeptidase A substrate specificity for N-terminal acidic amino-acid residues. Couvineau P; de Almeida H; Maigret B; Llorens-Cortes C; Iturrioz X PLoS One; 2017; 12(9):e0184237. PubMed ID: 28877217 [TBL] [Abstract][Full Text] [Related]
43. New insights into the importance of aminopeptidase A in hypertension. Mizutani S; Ishii M; Hattori A; Nomura S; Numaguchi Y; Tsujimoto M; Kobayshi H; Murohara T; Wright JW Heart Fail Rev; 2008 Sep; 13(3):273-84. PubMed ID: 17990103 [TBL] [Abstract][Full Text] [Related]
44. Lack of angiotensin II conversion to angiotensin III increases water but not alcohol consumption in aminopeptidase A-deficient mice. Faber F; Gembardt F; Sun X; Mizutani S; Siems WE; Walther T Regul Pept; 2006 Sep; 136(1-3):130-7. PubMed ID: 16889841 [TBL] [Abstract][Full Text] [Related]
45. Identification of threonine 348 as a residue involved in aminopeptidase A substrate specificity. Claperon C; Banegas-Font I; Iturrioz X; Rozenfeld R; Maigret B; Llorens-Cortes C J Biol Chem; 2009 Apr; 284(16):10618-26. PubMed ID: 19228697 [TBL] [Abstract][Full Text] [Related]
46. Pharmacological Characterization of Aprocitentan, a Dual Endothelin Receptor Antagonist, Alone and in Combination with Blockers of the Renin Angiotensin System, in Two Models of Experimental Hypertension. Trensz F; Bortolamiol C; Kramberg M; Wanner D; Hadana H; Rey M; Strasser DS; Delahaye S; Hess P; Vezzali E; Mentzel U; Ménard J; Clozel M; Iglarz M J Pharmacol Exp Ther; 2019 Mar; 368(3):462-473. PubMed ID: 30622171 [TBL] [Abstract][Full Text] [Related]
47. A pilot double-blind randomized placebo-controlled crossover pharmacodynamic study of the centrally active aminopeptidase A inhibitor, firibastat, in hypertension. Azizi M; Courand PY; Denolle T; Delsart P; Zhygalina V; Amar L; Lantelme P; Mounier-Vehier C; De Mota N; Balavoine F; Llorens-Cortes C J Hypertens; 2019 Aug; 37(8):1722-1728. PubMed ID: 30882604 [TBL] [Abstract][Full Text] [Related]
49. Aminopeptidase-induced elevations and reductions in blood pressure in the spontaneously hypertensive rat. Wright JW; Mizutani S; Murray CE; Amir HZ; Harding JW J Hypertens; 1990 Oct; 8(10):969-74. PubMed ID: 2174951 [TBL] [Abstract][Full Text] [Related]
50. Circulating aminopeptidase activities in men and women with essential hypertension. Sánchez-Agesta Ortega R; Arias de Saavedra-Alías JM; Liébana-Cañada A; Sánchez-Muñoz B; Martínez-Martos JM; Ramírez-Expósito MJ Curr Med Chem; 2013; 20(38):4935-45. PubMed ID: 23931276 [TBL] [Abstract][Full Text] [Related]
51. Hypertension and angiotensin II hypersensitivity in aminopeptidase A-deficient mice. Mitsui T; Nomura S; Okada M; Ohno Y; Kobayashi H; Nakashima Y; Murata Y; Takeuchi M; Kuno N; Nagasaka T; O-Wang J; Cooper MD; Mizutani S Mol Med; 2003; 9(1-2):57-62. PubMed ID: 12765341 [TBL] [Abstract][Full Text] [Related]
52. Investigation of the active site of aminopeptidase A using a series of new thiol-containing inhibitors. Chauvel EN; Coric P; Llorens-Cortès C; Wilk S; Roques BP; Fournié-Zaluski MC J Med Chem; 1994 Apr; 37(9):1339-46. PubMed ID: 7909847 [TBL] [Abstract][Full Text] [Related]
53. Synthesis and in vitro activities of new non-peptidic APA inhibitors. Inguimbert N; Coric P; Dhotel H; Bonnard E; Llorens-Cortes C; Mota N; Fournié-Zaluski MC; Roques BP J Pept Res; 2005 Feb; 65(2):175-88. PubMed ID: 15705162 [TBL] [Abstract][Full Text] [Related]
54. Potent and selective inhibition of zinc aminopeptidase A (EC 3.4.11.7, APA) by glutamyl aminophosphinic peptides: importance of glutamyl aminophosphinic residue in the P1 position. Georgiadis D; Vazeux G; Llorens-Cortes C; Yiotakis A; Dive V Biochemistry; 2000 Feb; 39(5):1152-5. PubMed ID: 10653662 [TBL] [Abstract][Full Text] [Related]
56. Conversion of brain angiotensin II to angiotensin III is critical for pressor response in rats. Wright JW; Tamura-Myers E; Wilson WL; Roques BP; Llorens-Cortes C; Speth RC; Harding JW Am J Physiol Regul Integr Comp Physiol; 2003 Mar; 284(3):R725-33. PubMed ID: 12433674 [TBL] [Abstract][Full Text] [Related]
57. Focus on Brain Angiotensin III and Aminopeptidase A in the Control of Hypertension. Wright JW; Mizutani S; Harding JW Int J Hypertens; 2012; 2012():124758. PubMed ID: 22792446 [TBL] [Abstract][Full Text] [Related]
58. Inhibition of vasopressinergic neurons by central injection of a specific aminopeptidase A inhibitor. Zini S; Demassey Y; Fournié-Zaluski MC; Bischoff L; Corvol P; Llorens-Cortès C; Sanderson P Neuroreport; 1998 Mar; 9(5):825-8. PubMed ID: 9579673 [TBL] [Abstract][Full Text] [Related]
59. Conversion of renal angiotensin II to angiotensin III is critical for AT2 receptor-mediated natriuresis in rats. Padia SH; Kemp BA; Howell NL; Fournie-Zaluski MC; Roques BP; Carey RM Hypertension; 2008 Feb; 51(2):460-5. PubMed ID: 18158338 [TBL] [Abstract][Full Text] [Related]
60. The effect of recombinant aminopeptidase A (APA) on hypertension in pregnant spontaneously hypertensive rats (SHRs). Ishii M; Hattori A; Numaguchi Y; Ma X; Nagasaka T; Tsujimoto M; Murohara T; Kobayashi H; Mizutani S Early Hum Dev; 2009 Sep; 85(9):589-94. PubMed ID: 19608358 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]